The ability to identify factors that predict efficacy of anti–tumor necrosis factor (TNF) agents is crucial if clinicians are to optimize treatment and minimize side effects and costs.
Over the past 20 years, the use of anti—tumor necrosis factor (TNF) agents has revolutionized the treatment of patients with inflammatory bowel disease (IBD) by allowing them to avoid the use of steroids, promoting mucosal healing, reducing hospitalizations and surgeries, and dramatically improving quality of life. However, primary nonresponse to these drugs or loss of response (LOR) over time due to immunogenicity or treatment-related side-effects are a concern.
Nonresponse to anti-TNF therapy occurs in 20% to 40% of patients in clinical trials and in 10% to 20% of patients in real-world scenarios; the incidence of secondary LOR ranges from 23% to 46% a year after treatment initiation. Thus, the abililty to identify factors that predict efficacy of these drugs is crucial if clinicians are to optimize treatment and minimize side effects and costs.
To this point, studies investigating predictive factors have produced controversial results, according to a review by Loris Riccardo Lopetuso, MD, PhD, and colleagues, published in International Journal of Molecular Sciences. The authors undertake this goal through a literature search on the predictive factors of the short- and long-term benefits of anti-TNF therapy in IBD patients, evaluating multiple patient-, disease-, and treatment-related factors for infliximab, adalimumab, golimumab, and certolizumab pegol in both controlled clinical trials and real-world studies.
The authors found the following factors to be predictive of response to anti-TNF treatment in clinical practice:
Patient-related factors:
Disease-related factors:
Treatment-related factors:
The review also lists factors that could be predictive of response to anti-TNF therapy, but that are not yet available in clinical practice. These factors, which could be seen in controlled trials, include genetic variants of particular genes in patients with CD.
“Clearly, in the future, the creation of specific algorithms with the combination of multiple variables could deeply improve their predictive baseline strength before starting [anti-TNF] agents,” the researchers note. “At the same time, in the era of precision medicine, newly diagnosed IBD patients will need to have their genetic, microbiome, and immune characteristics measured at time 0, then matched to the most appropriate biological or immunosuppressive treatment based on likelihood of response/adverse effects.”
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.